A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Inclusion criteria: * Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma as per IW-CLL 2008 criteria and require therapy based on meeting at least one of the following criteria: * Evidence of progressive marrow failure with anemia (hemoglobin \<11.0 g/L) and/or thrombocytopenia (platelets \<100 x 10\^9/L) * Massive (≥6 cm below the left costal margin), progressive, or symptomatic splenomegaly * Massive nodes (at least 10 cm longest diameter), progressive, or symptomatic lymphadenopathy * Progressive lymphocytosis with an increase of more than 50% over a 2-month period or LDT of \<6 months. * Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids * Constitutional symptoms, defined as 1 or more of the following: * unintentional weight loss \>10% within 6 months prior to screening * significant fatigue (inability to work or perform usual activities) fevers \>100.5° F or 38.0° C for 2 or more weeks prior to screening without evidence of infection * night sweats for more than 1 month prior to screening without evidence of infection * Relapsed after or refractory to at least one prior Chronic Lymphocytic Leukemia-directed therapy * Age greater than or equal to 18 years * ECOG Performance Status \<2 * Heme criteria at screening, unless significant bone marrow involvement of Chronic Lymphocytic Leukemia confirmed on biopsy: * Absolute Neutrophil Count (ANC) ≥500 cells/mm3 (0.5 x 1…